Pfizer's Lung Cancer Drug Shows Record-Breaking Results and Billion-Dollar Potential
TL;DR
Pfizer's drug Lorbrena has shown promising long-term results in a late-stage trial for advanced non-small cell lung cancer with the ALK mutation, potentially establishing it as the new standard treatment. The drug significantly extended progression-free survival and reduced brain metastases compared to Pfizer's older drug Xalkori. The findings will be presented at the American Society of Clinical Oncology annual meeting.
- Pfizer's drug for advanced lung cancer shows promising long-term trial results CNBC
- Trial results for new lung cancer drug are ‘off the charts’, say doctors The Guardian
- Lung cancer treatment: Pfizer's Lorbrena extends life in some non-small cell lung cancers NBC News
- Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data Reuters
- Lorlatinib Yields Longest Reported PFS in Advanced NSCLC OncLive
Want the full story? Read the original reporting
Read on CNBC